Pharma & Biotech

The proposed merger between Rallybio and the private firm Candid Therapeutics has drawn the attention of U.S. legal firms, casting...

For investors in Achieve Life Sciences, all roads lead to a single date: June 20, 2026. This is the deadline...

Vivani Medical finds itself balancing promising clinical developments against financial market realities. The biotechnology firm is targeting the high-growth weight-loss...

BioNxt Solutions has unveiled a strategic pivot designed to position the company at the forefront of one of the pharmaceutical...

Roche has secured significant regulatory approvals across two major markets, delivering a strategic boost to its high-margin diagnostics business. The...

For investors in Telix Pharmaceuticals, 2026 is shaping up to be a defining period. The company’s commercial prospects hinge on...

BioNTech's stock has faced significant headwinds from founder transitions and subdued financial forecasts. However, developments within its research pipeline offer...

Investors in biotechnology firm ImmunityBio are navigating a landscape of stark contrasts. The company's commercial prospects appear increasingly bright, driven...

Eli Lilly and Company is approaching a pivotal period marked by two significant catalysts. While the pharmaceutical giant's stock has...

Danish pharmaceutical giant Novo Nordisk has achieved a landmark regulatory victory with the U.S. Food and Drug Administration (FDA) granting...